Canadian Cardiovascular Society

Amyloid Education Series

Welcome to the Amyloid Education Series

The Canadian Cardiovascular Society’s Amyloid Education Series is designed to address the challenges associated with amyloid-related diseases. This educational program provides healthcare professionals with practical knowledge, evidence-based insights, and clinical tools to support the timely diagnosis, effective management, and optimal care of patients with amyloid-related conditions. 

Program Chairs:

Dr. Kareem Morant
Dr. Anil Gupta

Welcome to the CCS Amyloid Education Series, launched in 2024. With an aim to address the challenges posed by amyloid, this program will provide practical knowledge and tools that will empower healthcare professionals to effectively diagnose and manage patients with amyloid-related conditions.  

This multi-pronged and multi-modal program includes two MOC Section 1 accredited webinars, and two MOC Section 3 accredited programs. 

Part 1: Detecting Cardiac Amyloidosis: A Diagnostic Odyssey
Date: June 05, 2024 from 8:00 p.m. to 9:00 p.m ET 
Faculty: Dr. Margot Davis, Dr. Nathalie Ho, and Dr. Francois Tournoux 

Part 2: Cardiac Amyloidosis: Navigating the Diagnosis in Diverse Canadian Populations 
Date:
September 11, 2024 from 8:00 p.m. to 9:00 p.m ET 
Faculty: Dr. Kareem Morant, Dr. Nowell Fine and Dr. Michelle Mezei 

This program has received an educational grant from AstraZeneca and Pfizer. This program was developed by the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity, and balance.   

Welcome to the CCS Amyloid Education Series 2.0, launched in 2025. With an aim to address the challenges posed by amyloid, this program will provide practical knowledge and tools that will empower healthcare professionals to effectively diagnose and manage patients with amyloid-related conditions.  

This multi-pronged and multi-modal program includes three MOC Section 1 accredited webinars, and three MOC Section 3 accredited programs. 

Welcome to the CCS Amyloid Education Series 2.0, launched in 2025. With an aim to address the challenges posed by amyloid, this program will provide practical knowledge and tools that will empower healthcare professionals to effectively diagnose and manage patients with amyloid-related conditions.  

This multi-pronged and multi-modal program includes three MOC Section 1 accredited webinars, and three MOC Section 3 accredited programs. 

Part 1: Amyloidosis Uncovered: Pathophysiology, Clinical Clues, and Diagnostic Imaging – CCS Position Statement & Beyond 
Date: November 19, 2025 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Margot Davis, Dr. Natalie Ho, and Dr. Aws Almuhfleh

Part 2: Amyloidosis Management in 2025: Current and Future Therapies – CCS Position Statement & Beyond 
Date: December 11, 2025 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Anique Ducharme, Dr. Nowell Fine and Dr. Diego Delgado 

Part 3: Cases and Clinical Conundrums in Amyloidosis Management 
Date: March 25, 2026 from 8:00 p.m. to 9:00 p.m ET  
Faculty: Dr. Kareem Morant, Dr. Natalie Ho and Dr. Gary Small 

This program has received an educational grant from AstraZeneca and Pfizer. This program was developed by the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity, and balance. 

 

Back to top